BRPI0407097A - Antagonista do casr - Google Patents

Antagonista do casr

Info

Publication number
BRPI0407097A
BRPI0407097A BR0407097-6A BRPI0407097A BRPI0407097A BR PI0407097 A BRPI0407097 A BR PI0407097A BR PI0407097 A BRPI0407097 A BR PI0407097A BR PI0407097 A BRPI0407097 A BR PI0407097A
Authority
BR
Brazil
Prior art keywords
compound
antagonist
casr
casr antagonist
calcium
Prior art date
Application number
BR0407097-6A
Other languages
English (en)
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BRPI0407097A publication Critical patent/BRPI0407097A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

"ANTAGONISTA DO CaSR". A presente invenção refere-se a um composto representado pela seguinte fórmula (1), um sal farmaceuticamente aceitável deste ou uma forma oticamente ativa deste: em que cada símbolo é como definido no relatório descritivo. Um composto tendo uma ação antagonística do receptor sensível ao cálcio, uma composição farmacêutica que compreende o composto, particularmente um antagonista receptor de cálcio e uma droga terapêutica para a osteoporose são fornecidos.
BR0407097-6A 2003-04-23 2004-04-23 Antagonista do casr BRPI0407097A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
PCT/JP2004/005886 WO2004094362A1 (ja) 2003-04-23 2004-04-23 CaSRアンタゴニスト

Publications (1)

Publication Number Publication Date
BRPI0407097A true BRPI0407097A (pt) 2006-01-24

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407097-6A BRPI0407097A (pt) 2003-04-23 2004-04-23 Antagonista do casr

Country Status (30)

Country Link
US (4) US7304174B2 (pt)
EP (3) EP1619180B1 (pt)
JP (1) JP3751312B2 (pt)
KR (1) KR100696927B1 (pt)
CN (2) CN101723921A (pt)
AR (1) AR044075A1 (pt)
AT (1) ATE452121T1 (pt)
AU (1) AU2004232604C1 (pt)
BR (1) BRPI0407097A (pt)
CA (1) CA2513738C (pt)
CL (1) CL2004000868A1 (pt)
CO (1) CO5640091A2 (pt)
CY (1) CY1109880T1 (pt)
DE (1) DE602004024668D1 (pt)
DK (1) DK1619180T3 (pt)
ES (1) ES2337576T3 (pt)
HR (1) HRP20100042T1 (pt)
IL (1) IL169575A (pt)
MX (1) MXPA05007609A (pt)
MY (1) MY138734A (pt)
NO (1) NO20054868L (pt)
NZ (1) NZ541188A (pt)
PE (1) PE20050460A1 (pt)
PL (1) PL1619180T3 (pt)
PT (1) PT1619180E (pt)
RU (1) RU2315036C2 (pt)
SI (1) SI1619180T1 (pt)
TW (1) TWI329628B (pt)
WO (1) WO2004094362A1 (pt)
ZA (1) ZA200505587B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
WO2004106280A1 (ja) * 2003-05-28 2004-12-09 Japan Tobacco Inc. ＣａＳＲアンタゴニスト
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005077886A1 (en) * 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
AU2007240317B2 (en) 2006-04-20 2012-11-29 Amgen Inc. Stable emulsion formulations
EP2139462B1 (en) 2007-03-30 2014-01-22 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
AU2009255156B2 (en) * 2008-06-05 2013-03-14 Asahi Kasei Pharma Corporation Sulfonamide compound and application thereof
CN102307847A (zh) 2008-12-24 2012-01-04 第一三共株式会社 茚满基化合物
CN102307852B (zh) 2008-12-24 2013-12-18 第一三共株式会社 环状胺化合物
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
MX2011010031A (es) * 2009-03-26 2011-10-11 Japan Tobacco Inc Proceso para producir compuesto de acido carboxilico.
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル－環状アミン化合物
US8765676B2 (en) 2009-05-27 2014-07-01 Leo Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2643298A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
US20130244995A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2014033604A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3468550A4 (en) 2016-06-13 2020-02-12 Syneurx International (Taiwan) Corp. USE OF LITHIUM BENZOATE FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
CN118496313A (zh) * 2019-12-09 2024-08-16 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
IL300285A (en) * 2020-08-04 2023-04-01 Calcilytix Therapeutics Inc Formulations of triphenyl calcilytic compounds
US20220087961A1 (en) * 2020-09-18 2022-03-24 Calcilytix Therapeutics, Inc. Treatment methods of triphenyl calcilytic compounds
WO2024220796A1 (en) 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (pt) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
ES2256370T3 (es) * 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
WO1997037967A1 (en) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
DE69711519T2 (de) * 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
MY121054A (en) 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US6334338B1 (en) * 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
WO2000009491A1 (en) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
EP1112073A4 (en) 1998-08-12 2002-10-25 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
CN1150195C (zh) * 1998-10-23 2004-05-19 霍夫曼-拉罗奇有限公司 双环氮杂环
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
CA2382119A1 (en) * 1999-08-27 2001-03-08 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
CZ2003142A3 (cs) 2000-07-21 2003-06-18 Smithkline Beecham Corporation Kalcilytické sloučeniny
EP1308436B1 (en) * 2000-08-11 2008-10-15 Japan Tobacco Inc. Calcium receptor antagonists
JP2004514659A (ja) 2000-10-25 2004-05-20 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
MXPA03003688A (es) 2000-10-25 2003-08-07 Smithkline Beecham Corp Compuestos calciliticos.
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
WO2004106280A1 (ja) * 2003-05-28 2004-12-09 Japan Tobacco Inc. ＣａＳＲアンタゴニスト

Also Published As

Publication number Publication date
AR044075A1 (es) 2005-08-24
US7304174B2 (en) 2007-12-04
US20090326058A1 (en) 2009-12-31
EP1619180A1 (en) 2006-01-25
JP3751312B2 (ja) 2006-03-01
HK1083096A1 (en) 2006-06-23
NZ541188A (en) 2008-01-31
AU2004232604B8 (en) 2004-11-04
KR100696927B1 (ko) 2007-03-20
CO5640091A2 (es) 2006-05-31
CL2004000868A1 (es) 2005-01-21
CY1109880T1 (el) 2014-09-10
EP2189439A2 (en) 2010-05-26
HRP20100042T1 (hr) 2010-02-28
US20080255042A1 (en) 2008-10-16
ES2337576T3 (es) 2010-04-27
IL169575A (en) 2011-07-31
CA2513738C (en) 2010-04-06
AU2004232604C1 (en) 2008-06-05
US20050032796A1 (en) 2005-02-10
AU2004232604B2 (en) 2007-09-13
CN101723921A (zh) 2010-06-09
EP2308828A3 (en) 2013-05-22
KR20050094047A (ko) 2005-09-26
RU2005123985A (ru) 2006-01-27
EP1619180B1 (en) 2009-12-16
EP2308828A2 (en) 2011-04-13
NO20054868D0 (no) 2005-10-21
IL169575A0 (en) 2007-07-04
MXPA05007609A (es) 2005-09-30
AU2004232604A8 (en) 2004-11-04
AU2004232604A1 (en) 2004-11-04
WO2004094362A1 (ja) 2004-11-04
JPWO2004094362A1 (ja) 2006-07-13
PE20050460A1 (es) 2005-07-08
DK1619180T3 (da) 2010-03-29
US20120301552A1 (en) 2012-11-29
DE602004024668D1 (de) 2010-01-28
RU2315036C2 (ru) 2008-01-20
CN100577633C (zh) 2010-01-06
TWI329628B (en) 2010-09-01
SI1619180T1 (sl) 2010-04-30
MY138734A (en) 2009-07-31
EP2189439A3 (en) 2011-05-04
EP1619180A4 (en) 2006-05-24
TW200505823A (en) 2005-02-16
NO20054868L (no) 2005-12-20
ZA200505587B (en) 2006-09-27
ATE452121T1 (de) 2010-01-15
CN1741984A (zh) 2006-03-01
PL1619180T3 (pl) 2010-05-31
CA2513738A1 (en) 2004-11-04
PT1619180E (pt) 2009-12-29

Similar Documents

Publication Publication Date Title
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
EP1630157A4 (en) ANTAGONIST OF CASR
SE0401342D0 (sv) Therapeutic compounds
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
CL2004001347A1 (es) Compuestos derivados de 4-[(imidazol-4il)etinil]-piridina sustituidos; procedimientos de preparacion; composicion farmaceutica; y su uso en la elaboracion de un medicamento util para el tratamiento o prevencion de trastornos inducidos por el receptor
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
SE0402635D0 (sv) Chemical compounds
SE0303480D0 (sv) Benzofuranes
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
BRPI0409217A (pt) derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.